U.S., Nov. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07228325) titled 'Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis' on Nov. 06.
Brief Summary: The study will evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) responses of FMXIN002, an intranasal epinephrine powder, compared with the EpiPen(R) intramuscular autoinjector, after single and double doses, in healthy adults with a history of allergic rhinitis.
Study Start Date: Nov. 03
Study Type: INTERVENTIONAL
Condition:
Anaphylaxis
Allergy
Intervention:
DRUG: FMXIN002 single dose
Single dose of FMXIN002 epinephrine microspheres powder for nasal application, 4.0 mg, at normal conditions.
DRUG: Epinephr...